Once Weekly GLP-1 in Persons With Spinal Cord Injury

NCT03292315 on ClinicalTrials.gov · last registry update 2023-03-14

A small phase 4 — 5 participants, against a typical 75. The sponsor logged completion for 1 March 2020. Primary outcome, as filed: Body Weight. semaglutide is approved in the US, but not for prediabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P4
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: James J. Peters Veterans Affairs Medical Center
Sponsor type: Fed
Enrollment: 5
Started: 2018-10-16
Primary completion: 2020-03-01 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Body Weight

Conditions studied

Spinal Cord Injuries · Insulin Resistance · Pre Diabetes · Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.